title: [Hepatitis viruses infection situation in Mianyang of the Sichuan province].
abstract: OBJECTIVE
  To investigate the seroprevalence of hepatitis viruses in Mianyang of the Sichuan province.
  
  
  METHODS
  EIISA was used for detecting anti-HAV IgG, HBsAg/HBsAb, anti-HCV IgG and anti-HEV IgG of the serum samples. All sample were collected in Mianyang areas in 2007.
  
  
  RESULTS
  1352 samples were detected. The positive rates of anti-HAV, HBsAg/HBsAb, anti-HCV,and anti-HEV are 81.07% (1096/1352), 5.40% (73/1352) and 61.32% (829/1352), 0.37% (5/1352) and 49.26% (666/1352), respectively. The positive rate at different age group, for anti-HAV was 38.21% of 10-19 years old, 83% of 20-29 years old, 88% of 30-39 years old, 95.03% of 40-49 years old, 97% of 50-59 years old, 97.77% of 60-69 years old, 97.52% of > or =70 years old. For HBsAg/HBsAb were 5.65% or 50.83%, 10.0% or 68.0%, 5.20% or 78.80%, 5.97% or 78.11%, 6.50% or 62.50%, 1.12% or 51.40%, 4.96% or 30.58% at the same age group, respectively,for anti-HCV, was 0.33% of 10-19 years old, 0.80% of 30-39 years, 0.56% of 60-69 years old, 0.83% of > or =70 years old.For HEV-IgG was 26.58% of 10-19 years old, 42.0% of 20-29 years old, 55.22%-61.0% of 30-> or =70 years old, for anti-HEV IgM, was 10.06% (53/527) in the positive samples of HEV-IgG.
  
  
  CONCLUSIONS
  The inoculation againt HAV and HBV is enhanced in the young population. HBsAg carrier and HCV infection is decreasing. The HEV infection is actually increasing.
authors: Science City Hospital, Mianyang 621900, China.
authors: Li-ping
authors: LP
authors: Zhang
authors: Ping
authors: P
authors: Yang
authors: Feng-hua
authors: FH
authors: Li
authors: Yu
authors: Y
authors: Yan
authors: Ming
authors: M
authors: Wen
authors: Yu-rong
authors: YR
authors: Zhang
authors: Yong-zhen
authors: YZ
authors: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002681:China / Q000453:epidemiology; D005260:Female; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006506:Hepatitis A / Q000453:epidemiology / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood* / Q000145:classification; D006509:Hepatitis B / Q000453:epidemiology / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000453:epidemiology / Q000276:immunology; D006507:Hepatovirus / Q000145:classification / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D016036:Seroepidemiologic Studies; D055815:Young Adult
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000914:Antibodies, Viral; D006508:Hepatitis Antibodies; D007075:Immunoglobulin M; C044203:anti-IgM